Study on Hyperlipidemia Combined With Carotid Atherosclerosis With ShenJu Granules
NCT ID: NCT06166121
Last Updated: 2023-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
80 participants
INTERVENTIONAL
2023-09-20
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ShenJu
On the basis of standardized drug treatment for Hyperlipidemia combined with carotid atherosclerosis, participants who met the inclusion criteria were randomly given ShenJu intervention on the day of inclusion, taking it twice a day for 90 days.
ShenJu
One package per time, twice a day, 90 days of treatment
placebo
On the basis of standardized drug treatment for Hyperlipidemia combined with carotid atherosclerosis, participants who met the inclusion criteria were randomly given placebo granules on the day of inclusion, which were taken twice a day for 90 days (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
Placebo
One package per time, twice a day, 90 days of treatment (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ShenJu
One package per time, twice a day, 90 days of treatment
Placebo
One package per time, twice a day, 90 days of treatment (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age between 18-65 years old
3. Meet the diagnostic criteria for hyperlipidemia and accompanied by carotid arteriosclerosis
4. Meet the diagnostic criteria of TCM wet certificate: refer to the scoring standard of TCM Wet Disease Scale
Exclusion Criteria
2. Any other serious disease or condition such as: malignant tumor, uncontrolled severe hypertension, diabetic ketoacidosis (acute complication/vascular abnormality), arrhythmia, coagulation abnormalities
3. Have participated in another clinical study within 30 days prior to enrollment or have received a history of randomized ketoacidosis in this study
4. Pregnant women, women preparing to become pregnant and lactating women
5. Patients who are allergic to relevant Chinese medicine ingredients
6. Patients who have had a stent inserted
7. Patients who the investigator determines are not suitable to participate in this study
15 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Provincial Hospital of Traditional Chinese Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lei Wang,MD
Chief Physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China
WangLei
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lei Wang, M.D
Role: primary
Lei Wang, Doctor
Role: primary
Shuai Mao, Doctor
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YF2022-215
Identifier Type: -
Identifier Source: org_study_id